Suggested remit: To appraise the clinical and cost effectiveness of pexidartinib within its marketing authorisation for treating symptomatic tenosynovial giant cell tumour.
Topic has been suspended
Status Suspended
Decision Selected
Process STA 2018
ID number 1682

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
02 October 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of Pexidartinib for treating symptomatic tenosynovial giant cell tumour. However, the company have advised that The European Medicines Agency Committee for Medicinal Products (CHMP) have issued a negative opinion for Pexidartinib for treating symptomatic tenosynovial giant cell tumour adults in the European Union. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes.
02 October 2020 Suspended. Topic has been suspended
07 May 2020 Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
16 March 2020 (14:00) Scoping workshop (Manchester)
21 January 2020 - 18 February 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual